NCT05278208 2026-04-13Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsNationwide Children's HospitalPhase 1/2 Recruiting65 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT05092451 2026-03-18Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer CenterPhase 1/2 Recruiting80 enrolled
NCT06937866 2025-11-21Maintenance Zanzalintinib With Etoposide After HDCT in GCTIndiana UniversityPhase 1/2 Recruiting38 enrolled